Regeneron, Sanofi: Dupixent Meets Main Endpoints in Children With Severe Atopic Dermatitis
August 06 2019 - 9:57AM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SAN.FR,
SNY) on Tuesday said a phase 3 study of Dupixent to treat severe
atopic dermatitis in children ages 6 to 11 met its primary and
secondary endpoints.
The study showed that adding Dupixent to standard-of-care
topical corticosteroids significantly improved measures of overall
disease severity, skin clearing, itching and health-related quality
of life, the companies said, adding that Dupixent is the first
biologic to show positive results in the pediatric population.
Dupixent is approved in the U.S. and European Union to treat
people 12 years of age and older with moderate-to-severe atopic
dermatitis, the most common form of eczema.
Regeneron and Sanofi said they plan to submit the study results
to regulatory authorities, starting with the U.S. Food and Drug
Administration in the fourth quarter.
Regeneron, of Tarrytown, N.Y., created Dupixent and markets it
jointly in the U.S. with France's Sanofi under a 2007 collaboration
agreement. Sanofi markets the product internationally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 06, 2019 09:42 ET (13:42 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024